Pheton Holdings Denies Market Manipulation Amid 44% Stock Surge, Targets $300M Miami Micro-IPO
By ATTN Desk · Editorial oversight: Sean Han
Introduction
PHETON HOLDINGS LTD (ticker: PTHL) is a Beijing-based healthcare solutions provider specializing in brachytherapy treatment planning systems. Since its founding in 1998, the company has focused on software and related services that facilitate targeted radiation therapy for cancer patients. PTHL shares trade on the NASDAQ under the symbol PTHL, and as of August 1, 2025, the stock was priced at USD 0.8161, reflecting a 44.29% increase from the prior close.
Corporate Structure and Workforce
Pheton Holdings operates through its wholly owned subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd. The company has not disclosed its headcount, but its activities, including IPO preparation and product development, suggest that it employs cross-functional teams in software engineering, medical physics, regulatory affairs, and investor relations. Public disclosures and LinkedIn insights indicate that employees typically possess advanced technical qualifications or relevant financial and legal expertise to support research and development as well as capital market activities.
Brachytherapy by Amit Gaur
Recent Developments
On August 1, 2025, Pheton issued a Form 6-K and a related press release denying any involvement in market manipulation or undisclosed acquisition discussions with Gilead Sciences. The company attributed recent share-price fluctuations and takeover rumors published by a third-party source to misleading information. Management announced plans to engage with Nasdaq, market makers, and regulatory authorities to address misinformation and protect shareholder interests.
Two Schedule 13G/A amendments filed on July 30, 2025, report zero beneficial ownership by several institutional and individual investors, indicating that no single party exercises control over PTHL’s Class A ordinary shares.
Additionally, a LinkedIn post dated August 2025 highlights Pheton’s intention to pursue a US micro-IPO targeting USD 300 million on the Miami International Exchange, indicating the company’s objective to raise capital for growth.
Financial and Strategic Analysis
On August 1, 2025, daily trading data showed:
| Metric | Value |
|---|---|
| Price | USD 0.8161 |
| Day’s Volume | 5,255,639 |
| 52-Week Range | 0.60 – 32.00 |
| Market Capitalization | USD 12.54 M |
| Enterprise Value | USD 6.63 M |
| Price/Sales (TTM) | 24.98 |
| Price/Book (MRQ) | 2.03 |
| Profit Margin (TTM) | –147.39% |
| Return on Assets (TTM) | –11.55% |
| Return on Equity (TTM) | –20.35% |
| Revenue (TTM) | USD 448.2 k |
| Net Income (TTM) | –USD 660.6 k |
| Total Cash (MRQ) | USD 6.16 M |
| Total Debt/Equity (MRQ) | 4.01% |
| Levered Free Cash Flow (TTM) | –USD 1.48 M |
The company reported negative margins and cash burn in its latest trailing twelve-month period. However, a cash position relative to debt suggests short-term liquidity. Management’s capital-raising initiatives, including the proposed micro-IPO, aim to enhance resources for product development and market expansion.
Market Position and Industry Context
Pheton operates in the market for brachytherapy treatment-planning systems, which is a segment of radiation oncology software. Its main product, the Treatment Planning System, utilizes algorithms for radioactive source placement to optimize tumor targeting while minimizing damage to healthy tissue. The global brachytherapy equipment and software market is influenced by the rising incidence of cancer and the demand for precision therapies. Pheton’s commitment to governance and transparency, as shown in its investor communications, aims to foster confidence among healthcare providers and investors.
tl;dr
On August 1, 2025, Pheton Holdings Ltd denied any involvement in stock manipulation or acquisition rumors, attributing a 44.29% share increase to misleading reports and announcing plans to cooperate with Nasdaq and regulators. Two Schedule 13G/A amendments filed on July 30, 2025, confirm that no single entity holds beneficial ownership. The company plans a USD 300 million micro-IPO on the Miami International Exchange to finance its brachytherapy software development. Financials reflect negative profitability but a solid cash position.